Pancreatic Microbiome May Hold the Key To Better Treatment
Dr. Deirdre Cohen’s research into the pancreatic microbiome has found that gut bacteria may directly influence the effectiveness of immunotherapy.
Genomic Profiling of my Pancreatic Cancer Gave me a New Lease on Life
When standard treatment did not work for Roy Vinke’s pancreatic cancer, he had genomic profiling done. A mutation was found, changing his treatment plan.
Targeting AXL May Improve Chemotherapy for Pancreatic Cancer
Dr. Shaalan Beg describes a clinical trial using the kinase inhibitor bemcentinib along with chemotherapy as a way to slow down or stop pancreatic cancer.
Collaborative Multi-Center Immunotherapy Trial Targets CD40 and PD-1
Dr. Mark O’Hara outlines a collaborative clinical trial of two immunotherapy agents–a checkpoint inhibitor and a monoclonal antibody–plus standard chemotherapy.
Keytruda Runner-Up for Science Breakthrough of the Year
The Lustgarten Foundation shares the story that Keytruda (pembrolizumab) is a runner-up in Science magazine’s Breakthrough of the year.
Chemotherapy, Immunotherapy, and Radiation for Locally Advanced Pancreatic Cancer
A clinical trial is testing chemotherapy that enhances the action of two immunotherapy drugs and SBRT to stop locally advanced pancreatic cancer.
Presurgical Treatment for Pancreatic Cancer That Is Removable
A clinical trial looks at immunotherapy plus vitamin D plus standard chemotherapy before surgery to remove pancreatic cancer.
An Immunotherapy Game Changer
Immunotherapy with Keytruda (pembrolizumab) is approved for use in cancer patients with certain genetic defects in their tumors.
Immunotherapy to Help Shrink Pancreatic Tumors for Surgery
Researchers are looking at adding checkpoint drugs–a type of immunotherapy–to standard chemoradiation to shrink pancreatic cancer for surgery.
